IGKV1D-22 and skin cancer: S100A8/A9 are strongly up-regulated in breast [47], lung [48], gastric [49], colorectal [50], pancreatic [51], skin cancers [52] and prostate cancer [53], in inflammation associated with cancer [45] and altered S100A9 expression in carcinomas can lead to chemoresistance [54].